Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs)
$105.93
pos +0.46
+0.43%
Today's Range: 104.55 - 106.21 | GILD Avg Daily Volume: 13,393,200
Last Update: 09/23/14 - 12:41 PM EDT
Volume: 5,193,626
YTD Performance: 40.44%
Open: $104.71
Previous Close: $105.47
52 Week Range: $58.81 - $110.64
Oustanding Shares: 1,511,670,456
Market Cap: 160,176,601,518
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 13 15
Moderate Buy 1 1 1 2
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.33 1.33 1.31 1.32
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 23.86
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
23.86 23.80 28.93
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
29.89% 65.16% 450.18%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.50 0.41 0.12
Net Income 18.80 0.06 0.02
EPS 10.80 0.18 0.06
Earnings for GILD:
EBITDA 4.87B
Revenue 11.20B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.64 $2.22 $7.26 $9.07
Number of Analysts 3 3 3 3
High Estimate $1.85 $2.81 $8.34 $10.13
Low Estimate $1.35 $1.52 $5.51 $7.31
Prior Year $0.50 $0.52 $1.92 $7.26
Growth Rate (Year over Year) 227.33% 326.28% 278.30% 24.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
I'm mostly underweight, given the shoddy performance, but I am loading up on these small E&Ps.
Bullish
Sep 19, 2014 | 7:41 AM EDT
Shares of GILD now seen reaching $139, according to Citi. Estimates also upped, given a higher volume outlook for Hepatitis C treatment...

Rotating Into Blue Chips Real Money Pro($)

Three attractively priced large-caps I would add on a dip.

Fitz Bits: A Tightrope Walk Real Money Pro($)

With the market at its highs and the massive risk, that's what being a money manager currently entails.
 Hepatitis C therapies are the pacesetters.

Seize On Those Overreactions Real Money Pro($)

I caught two such trades in the past few days by staying light on my feet.

Question of the Day Real Money Pro($)

Who DOESN'T like Gilead (GILD)?
Update
Sep 04, 2014 | 7:34 AM EDT
Robert W. Baird & Co. Inc Health Care Conference (Day 2 of 2) - 09/03/14 - 09/04/14 New York City, NY
Update
Sep 03, 2014 | 6:56 AM EDT
Citi Biotech Conference 
Yep, the bets for the rest of 2014 are being placed.

Columnist Conversations

Market is slightly down at midday. NASDAQ and Russell 2000 outperforming S&P 500 and DJIA, the opposite s...
With the RUT now up on the day, I think the market has hit a near-term bottom and is likely to meander back to...
VIPS pulled backed nicely from the resistance discussed in the last article and has triggered again on the buy...
The 50 day moving average got some attention yesterday when it crossed below the 200 day average on the Russel...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.